Ipatasertib

Drug Profile

Ipatasertib

Alternative Names: GCD 0068; GDC-0068; RG-7440

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Array BioPharma
  • Developer Chugai Pharmaceutical; Genentech
  • Class Antineoplastics; Heterocyclic bicyclo compounds; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Gastrointestinal cancer; Prostate cancer
  • Phase I Solid tumours

Most Recent Events

  • 09 Mar 2017 Hoffmann-La Roche plans a phase III trial for Prostate cancer (Metastatic disease, Combination therapy, First-line therapy, Hormone refractory) in USA, Austria, Brazil, Canada, Costa Rica, Denmark, Greece, Hungary, Israel, South Korea, Poland, Portugal and Slovenia (NCT03072238)
  • 07 Oct 2016 Efficacy data from a phase I/II trial in Prostate cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top